253 related articles for article (PubMed ID: 8538480)
1. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
Schram JH; Boerrigter PJ; The TY
Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
[TBL] [Abstract][Full Text] [Related]
2. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate).
Alwers R; Urdinola J; Onatra W; Sánchez F; Posso H
Maturitas; 1999 May; 32(1):41-50. PubMed ID: 10423715
[TBL] [Abstract][Full Text] [Related]
3. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
[TBL] [Abstract][Full Text] [Related]
4. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.
Hänggi W; Lippuner K; Riesen W; Jaeger P; Birkhäuser MH
Br J Obstet Gynaecol; 1997 Jun; 104(6):708-17. PubMed ID: 9197875
[TBL] [Abstract][Full Text] [Related]
5. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate.
Lemay A; Dodin S; Cédrin I; T-Lemay L
Clin Endocrinol (Oxf); 1995 Apr; 42(4):341-51. PubMed ID: 7750187
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy: lipid responses to continuous combined oestrogen and progestogen versus oestrogen monotherapy.
Metka M; Hanes V; Heytmanek G
Maturitas; 1992 Aug; 15(1):53-9. PubMed ID: 1326708
[TBL] [Abstract][Full Text] [Related]
7. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3.
Tuppurainen M; Heikkinen AM; Penttilä I; Saarikoski S
Maturitas; 1995 Jun; 22(1):55-61. PubMed ID: 7666817
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of two levonorgestrel-containing hormone replacement therapy regimens of efficacy and tolerability variables.
Gräser T; Rössner P; Schubert K; Müller A; Bönisch U; Oettel M
Maturitas; 1997 Dec; 28(2):169-79. PubMed ID: 9522325
[TBL] [Abstract][Full Text] [Related]
9. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism.
Wollter-Svensson LO; Stadberg E; Andersson K; Mattsson LA; Odlind V; Persson I
Maturitas; 1995 Nov; 22(3):199-205. PubMed ID: 8746877
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
11. Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation.
Koninckx PR; Lauweryns JM; Cornillie FJ
Maturitas; 1993 Mar; 16(2):97-110. PubMed ID: 8387151
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effect of two hormonal preparations in postmenopausal women.
Bissonnette F; Lussier-Cacan S; Fugère P; Bérubé S
Maturitas; 1997 Jul; 27(3):275-84. PubMed ID: 9288700
[TBL] [Abstract][Full Text] [Related]
13. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.
Hirvonen E; Cacciatore B; Wahlström T; Rita H; Wilén-Rosenqvist G
Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():26-31. PubMed ID: 9389780
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.
Vigna GB; Donegà P; Zanca R; Barban A; Passaro A; Pansini F; Bonaccorsi G; Mollica G; Fellin R
Metabolism; 2002 Nov; 51(11):1463-70. PubMed ID: 12404199
[TBL] [Abstract][Full Text] [Related]
15. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report.
Campagnoli C; Biglia N; Lanza MG; Lesca L; Peris C; Sismondi P
Maturitas; 1994 May; 19(1):25-31. PubMed ID: 7935029
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
[TBL] [Abstract][Full Text] [Related]
17. Randomized cross-over study of a 21-day versus a 28-day hormone replacement therapy (HRT).
McCarthy T; Dramusic V; Carter R; Costales A; Ratnam SS
Maturitas; 1995 Jun; 22(1):13-23. PubMed ID: 7666812
[TBL] [Abstract][Full Text] [Related]
18. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
[TBL] [Abstract][Full Text] [Related]
19. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
Maturitas; 2004 Nov; 49(3):253-63. PubMed ID: 15488354
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
van der Mooren MJ; Demacker PN; Thomas CM; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1992 Nov; 47(2):153-60. PubMed ID: 1459329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
